QuickVue At-Home OTC COVID-19, 2 test/kit thumbnail 1 QuickVue At-Home OTC COVID-19, 2 test/kit thumbnail 2 QuickVue At-Home OTC COVID-19, 2 test/kit thumbnail 3 QuickVue At-Home OTC COVID-19, 2 test/kit thumbnail 4
Quidel QuickVue At-Home OTC COVID-19, 2 test/kit $23.50/Kit of 2 MedPlus 20402

* Image shown for reference purposes only. Actual product appearance may vary. Please read product description for full and accurate details.

- QuickVue At-Home OTC COVID-19, 2 test/kit (20402)

By Quidel

$23.50 / Kit of 2

MSRP $31.72 You Save $8.22

Sold & Shipped by MedPlus
In Stock
Typically Ships Within 24 Hours
Price Match Guarantee
Calculate shipping
Share this:

What you get:

  • Condition: New
  • Brand: Quidel
  • Product ID / Part Number: 20402
  • Packages/Order: 1
  • Package Type: Kit
  • Total Units: 2
  • Order Size: Kit
  • Unit Price: $11.75
Have a question ?

Introducing the QuickVue At-Home OTC COVID-19 Test, 2 test/kit
Take 10 Minutes. Take Charge.

Fast. Easy. Ready When You Are.
QuickVue At-Home OTC COVID-19 Test lets you get rapid results, in the privacy of your own home. Available over-the-counter, everything you need is in the package and taking the test is simple.

Now, the QuickVue At-Home OTC COVID-19 Test utilizes trusted technology used for decades by healthcare professionals and makes simple, easy-to-use COVID-19 tests accessible for the good of our families, our communities and the world.

Features/Benefits:
QUICKVUE SARS ANTIGEN TEST
The test is authorized for home use with self-collected anterior nasal (nares) swab samples in individuals aged 2 and older. This test is also authorized for home use for individuals aged 2 through 14 with an adult performing the test. The test is intended to be used twice over two to three days, with at least 24 hours and no more than 36 hours between tests.

Frequently Asked Questions
How Does the QuickVue At-Home OTC COVID-19 Test Work?
The test uses a gentle self-collected anterior nasal (nares) swab sample to determine a positive or negative COVID-19 result. The swab is swirled in a tube of reagent solution, then removed, before a test strip is inserted. After ten minutes, you can take the strip out of the tube and see your results.

Who is Quidel Corporation?
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia, Solana, Lyra, Triage and QuickVue, Quidel's comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world.

What is the history of the QuickVue brand?
The QuickVue brand launched in 1986 with visually read rapid diagnostics focusing on women's health and respiratory diseases. In 1999, QuickVue Influenza A+B was the first visually read rapid test approved by the FDA for professional use. QuickVue At-Home OTC COVID-19 Test utilizes the same technology used for decades by healthcare professionals and by the QuickVue SARS Antigen Test used in professional settings, receiving emergency use authorization (EUA) by the FDA in December 2020.

What is the accuracy of the test?
In a clinical study, the QuickVue At-Home OTC COVID-19 Test identified positive cases 83.5% of the time, and identified negative cases 99.2% of the time
(83.5% PPA, and 99.2% NPA, respectively), when compared to PCR.


FOR FDA EMERGENCY USE AUTHORIZATION (EUA) ONLY.
The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests. This home test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older. This home test has not been FDA cleared or approved, but has been authorized by the FDA under an Emergency Use Authorization (EUA) for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This home test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 360bbb-3(b)(1), unless authorization is terminated or revoked sooner.

About Quidel and its QuickVue:
At-Home OTC COVID-19 Test
Quidel is a California-based leading diagnostic manufacturer focused on improving the quality of healthcare throughout the globe. As a trusted innovator in the medical device industry for over 40 years, Quidel launched the QuickVue brand in 1986 with visually read rapid diagnostics focusing on women's health and respiratory diseases. In 1999, QuickVue Influenza A+B was the first visually read rapid test cleared by the FDA for professional use.

SKU: QUI 20402
Shipping Weight: 12 lbs 50 ounces
HCPCS: EUA210269

Flat Rate $9.95 in Continental US. Drop Ship $15.00. Exclusions apply. F.O.B. Destination greater than $2,000 + $30 ship charge + (FRC) of 1.35% on product total. FRC % is subject to change w/o notice.

No Returns, All Sales Final.

Introducing the QuickVue At-Home OTC COVID-19 Test, 2 test/kit
Take 10 Minutes. Take Charge.

Fast. Easy. Ready When You Are.
QuickVue At-Home OTC COVID-19 Test lets you get rapid results, in the privacy of your own home. Available over-the-counter, everything you need is in the package and taking the test is simple.

Now, the QuickVue At-Home OTC COVID-19 Test utilizes trusted technology used for decades by healthcare professionals and makes simple, easy-to-use COVID-19 tests accessible for the good of our families, our communities and the world.

Features/Benefits:
QUICKVUE SARS ANTIGEN TEST
The test is authorized for home use with self-collected anterior nasal (nares) swab samples in individuals aged 2 and older. This test is also authorized for home use for individuals aged 2 through 14 with an adult performing the test. The test is intended to be used twice over two to three days, with at least 24 hours and no more than 36 hours between tests.

Frequently Asked Questions
How Does the QuickVue At-Home OTC COVID-19 Test Work?
The test uses a gentle self-collected anterior nasal (nares) swab sample to determine a positive or negative COVID-19 result. The swab is swirled in a tube of reagent solution, then removed, before a test strip is inserted. After ten minutes, you can take the strip out of the tube and see your results.

Who is Quidel Corporation?
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia, Solana, Lyra, Triage and QuickVue, Quidel's comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world.

What is the history of the QuickVue brand?
The QuickVue brand launched in 1986 with visually read rapid diagnostics focusing on women's health and respiratory diseases. In 1999, QuickVue Influenza A+B was the first visually read rapid test approved by the FDA for professional use. QuickVue At-Home OTC COVID-19 Test utilizes the same technology used for decades by healthcare professionals and by the QuickVue SARS Antigen Test used in professional settings, receiving emergency use authorization (EUA) by the FDA in December 2020.

What is the accuracy of the test?
In a clinical study, the QuickVue At-Home OTC COVID-19 Test identified positive cases 83.5% of the time, and identified negative cases 99.2% of the time
(83.5% PPA, and 99.2% NPA, respectively), when compared to PCR.


FOR FDA EMERGENCY USE AUTHORIZATION (EUA) ONLY.
The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests. This home test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older. This home test has not been FDA cleared or approved, but has been authorized by the FDA under an Emergency Use Authorization (EUA) for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This home test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 360bbb-3(b)(1), unless authorization is terminated or revoked sooner.

About Quidel and its QuickVue:
At-Home OTC COVID-19 Test
Quidel is a California-based leading diagnostic manufacturer focused on improving the quality of healthcare throughout the globe. As a trusted innovator in the medical device industry for over 40 years, Quidel launched the QuickVue brand in 1986 with visually read rapid diagnostics focusing on women's health and respiratory diseases. In 1999, QuickVue Influenza A+B was the first visually read rapid test cleared by the FDA for professional use.MedPlus:
MedPlus Services USA, exclusively for medical and dental distributors, is your one-stop, single source for purchasing medical and dental products and supplies at competitive prices. With over 300 healthcare and dental manufacturers' products in stock and available from our warehouses, you are well positioned to meet the needs of your customer. More importantly, you will be competitive in today's challenging marketplace. MedPlus Services allows you to bundle your product purchases from manufacturers like: 3M, BD, Covidien/Kendall, Alere, Smith & Nephew and over 300 more onto one single purchase order.

There are no reviews for this product yet.

Log in to write a review

Alternative Supplies

Related Supplies

Product

10 panel

$202.65
Box of 25
Product

10 Panel (CLIA Waived)

$97.80
Case of 25